169 related articles for article (PubMed ID: 9387204)
1. Risk factors and prevention of vascular complications in polycythemia vera.
Barbui T; Finazzi G
Semin Thromb Hemost; 1997; 23(5):455-61. PubMed ID: 9387204
[TBL] [Abstract][Full Text] [Related]
2. Treatment of polycythemia vera.
Barbui T; Finazzi G
Haematologica; 1998 Feb; 83(2):143-9. PubMed ID: 9549926
[TBL] [Abstract][Full Text] [Related]
3. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial.
Landolfi R; Marchioli R
Semin Thromb Hemost; 1997; 23(5):473-8. PubMed ID: 9387206
[TBL] [Abstract][Full Text] [Related]
4. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
Finazzi G;
Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715
[TBL] [Abstract][Full Text] [Related]
5. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
[TBL] [Abstract][Full Text] [Related]
6. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
Finazzi G
Semin Thromb Hemost; 2006 Apr; 32(3):276-82. PubMed ID: 16673282
[TBL] [Abstract][Full Text] [Related]
8. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
9. Front-line therapy in polycythemia vera and essential thrombocythemia.
Barbui T; Finazzi MC; Finazzi G
Blood Rev; 2012 Sep; 26(5):205-11. PubMed ID: 22784966
[TBL] [Abstract][Full Text] [Related]
10. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
11. Laboratory investigations and prediction of thrombotic risk in polycythemia vera.
Boneu B
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):183-5. PubMed ID: 8036139
[TBL] [Abstract][Full Text] [Related]
12. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
13. Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients.
Bachleitner-Hofmann T; Grumbeck E; Gisslinger H
Thromb Res; 2003; 112(4):229-32. PubMed ID: 14987916
[TBL] [Abstract][Full Text] [Related]
14. Expertise-based management in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
[TBL] [Abstract][Full Text] [Related]
15. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.
Marchioli R; Finazzi G; Landolfi R; Kutti J; Gisslinger H; Patrono C; Marilus R; Villegas A; Tognoni G; Barbui T
J Clin Oncol; 2005 Apr; 23(10):2224-32. PubMed ID: 15710945
[TBL] [Abstract][Full Text] [Related]
16. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
[TBL] [Abstract][Full Text] [Related]
17. Erythromelalgia and vascular complications in polycythemia vera.
Michiels JJ
Semin Thromb Hemost; 1997; 23(5):441-54. PubMed ID: 9387203
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs.
Crisà E; Venturino E; Passera R; Prina M; Schinco P; Borchiellini A; Giai V; Ciocca Vasino MA; Bazzan M; Vaccarino A; Boccadoro M; Ferrero D
Ann Hematol; 2010 Jul; 89(7):691-9. PubMed ID: 20146064
[TBL] [Abstract][Full Text] [Related]
19. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
20. The haematocrit and platelet target in polycythemia vera.
Di Nisio M; Barbui T; Di Gennaro L; Borrelli G; Finazzi G; Landolfi R; Leone G; Marfisi R; Porreca E; Ruggeri M; Rutjes AW; Tognoni G; Vannucchi AM; Marchioli R;
Br J Haematol; 2007 Jan; 136(2):249-59. PubMed ID: 17156406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
